FDA Inspection 1068951 — Evonik Rexim (Nanning) Pharmaceutical Co. Ltd.
The FDA completed an inspection of Evonik Rexim (Nanning) Pharmaceutical Co. Ltd. on Sep 28, 2018 in Nanning. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Sep 28, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Nanning (China)